These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
291 related items for PubMed ID: 9662590
21. Evaluation of radioiodine therapy in differentiated thyroid cancer subjects with elevated serum thyroglobulin and negative whole body scan using 131I with emphasize on the thallium scintigraphy in these subgroups. Zakani A, Saghari M, Eftekhari M, Fard-Esfahani A, Fallahi B, Esmaili J, Assadi M. Eur Rev Med Pharmacol Sci; 2011 Oct; 15(10):1215-21. PubMed ID: 22165686 [Abstract] [Full Text] [Related]
22. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. Chung JK, So Y, Lee JS, Choi CW, Lim SM, Lee DS, Hong SW, Youn YK, Lee MC, Cho BY. J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315 [Abstract] [Full Text] [Related]
23. Value of combined technetium-99m hydroxy methylene diphosphonate and thallium-201 imaging in detecting bone metastases from thyroid carcinoma. Alam MS, Takeuchi R, Kasagi K, Misaki T, Miyamoto S, Iida Y, Hidaka A, Konishi J. Thyroid; 1997 Oct; 7(5):705-12. PubMed ID: 9349573 [Abstract] [Full Text] [Related]
24. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan? Salvatori M, Perotti G, Rufini V, Maussier ML, Dottorini M. Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184 [Abstract] [Full Text] [Related]
25. Thyroglobulin radioimmunoassay and 131I scintigraphy in patients with differentiated thyroid carcinoma. Lindegaard MW, Paus E, Høie J, Kullman G, Stenwig AE. Acta Chir Scand; 1988 Feb; 154(2):141-5. PubMed ID: 3354295 [Abstract] [Full Text] [Related]
26. Thyrotropin variations may explain some positive radioiodine therapy scans in patients with negative diagnostic scans. Zanotti-Fregonara P, Keller I, Rubello D, Calzada-Nocaudie M, Devaux JY, Hindié E. J Endocrinol Invest; 2009 Mar; 32(3):267-71. PubMed ID: 19542747 [Abstract] [Full Text] [Related]
32. The role of iodine-131 and thallium-201 imaging and serum thyroglobulin in the management of differentiated thyroid carcinoma. Dadparvar S, Krishna L, Brady LW, Slizofski WJ, Brown SJ, Chevres A, Micaily B. Cancer; 1993 Jun 01; 71(11):3767-73. PubMed ID: 8490927 [Abstract] [Full Text] [Related]
33. Routine 201Tl scintigraphy in the follow-up of patients with differentiated thyroid carcinoma: diagnostic accuracy and clinical impact. Hsu CC, Chen YW, Huang YF, Chuang YW. Nucl Med Commun; 2007 Sep 01; 28(9):681-7. PubMed ID: 17667746 [Abstract] [Full Text] [Related]
35. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. J Clin Endocrinol Metab; 2000 Jan 01; 85(1):175-8. PubMed ID: 10634383 [Abstract] [Full Text] [Related]
36. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy. Lind P, Gallowitsch HJ. Acta Med Austriaca; 1996 Jan 01; 23(1-2):69-75. PubMed ID: 8767519 [Abstract] [Full Text] [Related]
37. The rational use of 201Tl scintigraphy in the evaluation of differentiated thyroid cancer. Nĕmec J, Zamrazil V, Pohunková D, Röhling S, Holub V. Eur J Nucl Med; 1984 Jan 01; 9(6):261-4. PubMed ID: 6745296 [Abstract] [Full Text] [Related]